Effect of Thoracoscopic Lobectomy in the Treatment of Clinical Efficacy,Pulmonary Function and Pentraxin-3 Level in Elderly Patients with Non-small Cell Lung Cancer
Objective To analyze the effects of thoracoscopic lobectomy on the clinical efficacy,pulmonary function and serum Pentraxin-3 level of elderly patients with NSCLC.Methods 122 patients with NSCLC who were admitted to our hospital from March 2019 to March 2021 were selected,and according to different surgical treatment plans,they were divided into control group(traditional open lobectomy,n=59)and study group(thoracoscopic lobectomy,n=63).The clinical efficacy,perioperative conditions,forced expiratory volume in Ⅰ second(FEV1),minute ventilation(MV),peak expiratory flow(PEF),Pentraxin-3,Human epididymal protein 4(HE4),pentameric protein(PTX3),complication rate and 1-year survival rate,recurrence rate were compared between the two groups.Results The clinical efficacy of the study group was higher than that of the control group,with statistical significance,and the difference was statistically significant(P＜0.05).The postoperative FEV1,MV and PEF of the two groups were decreased,and the postoperative FEV1,MV and PEF of the study group were higher than those of the control group(P＜0.05).The levels of Pentraxin-3,HE4 and PTX3 in the two groups decreased after operation,and the levels of Pentraxin-3,HE4 and PTX3 in the study group were lower than those in the control group(P＜0.05).The incidence of complications in the control group was higher than that in the study group(P＜0.05).There was no significant difference in the survival rate between the two groups(P＞0.05);the recurrence rate in the study group was lower than that in the control group(P＜0.05).Conclusion The thoracoscopic lobectomy for elderly patients with NSCLC has a definite clinical effect,has little effect on lung function,and can improve the levels of Pentraxin-3,HE4,and PTX3,has a high safety,which is worthy of widespread clinical promotion.
万方数据
维普
